COMPASS Pathways (NASDAQ:CMPS) Receives Overweight Rating from Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "overweight" rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock. Cantor Fitzgerald's price objective would suggest a potential upside of 189.86% from the company's previous close.

Several other analysts have also commented on CMPS. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a report on Monday, May 12th. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Finally, Stifel Nicolaus began coverage on COMPASS Pathways in a research report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $18.83.

COMPASS Pathways Stock Down 1.9%

Shares of COMPASS Pathways stock traded down $0.08 on Tuesday, reaching $4.14. The company's stock had a trading volume of 1,034,142 shares, compared to its average volume of 850,201. The company has a market capitalization of $384.39 million, a price-to-earnings ratio of -1.88 and a beta of 2.27. The firm's fifty day simple moving average is $3.52 and its two-hundred day simple moving average is $3.91. COMPASS Pathways has a 52 week low of $2.49 and a 52 week high of $8.54. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03. Equities analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Hedge Funds Weigh In On COMPASS Pathways

Several large investors have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its position in shares of COMPASS Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company's stock valued at $686,000 after acquiring an additional 71,112 shares in the last quarter. Woodline Partners LP lifted its position in shares of COMPASS Pathways by 279.9% in the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock valued at $5,019,000 after acquiring an additional 1,292,927 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of COMPASS Pathways in the first quarter valued at about $657,000. Nantahala Capital Management LLC lifted its position in shares of COMPASS Pathways by 182.9% in the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock valued at $8,092,000 after acquiring an additional 1,829,232 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of COMPASS Pathways by 49.8% in the first quarter. Royal Bank of Canada now owns 89,446 shares of the company's stock valued at $256,000 after acquiring an additional 29,733 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.